Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL27944889 | 0.96 | MEN1 (0.83) | — | |
| Tromethamine SCHEMBL17484 | 0.95 | MEN1 (1.00) | — | |
| Tromethamine SCHEMBL975 | 0.95 | — | — | |
| Tromethamine SCHEMBL3696191 | 0.95 | — | — | |
| Tromethamine SCHEMBL445853 | 0.91 | MEN1 (0.91) | — | |
| Tromethamine SCHEMBL6427079 | 0.91 | — | — | |
| Tromethamine SCHEMBL9298764 | 0.91 | — | — | |
| Tromethamine SCHEMBL2263148 | 0.91 | MEN1 (0.91) | — | |
| Tromethamine SCHEMBL6063594 | 0.91 | — | — | |
| Tromethamine SCHEMBL2313359 | 0.91 | MEN1 (0.91) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629382-B2 | Therapy | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-05-19 | — | — | US | disclosed |
| EP-4734985-A1 | PREVENTION, INHIBITION OR TREATMENT OF CONDITIONS OR DISORDERS MEDIATED BY UROCANATE REDUCTASE | IMPLEXION PHARMA AB (SE) | 2026-05-06 | — | — | EP | disclosed |
| US-12616193-B2 | 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility | SPERMATECH AS (NO) | 2026-05-05 | — | — | US | disclosed |
| US-12503476-B2 | Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria | QURETECH BIO AB (SE) | 2025-12-23 | — | — | US | disclosed |
| US-12472168-B2 | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria | QURETECH BIO AB (SE) | 2025-11-18 | — | — | US | disclosed |
| US-20250066367-A1 | Pyrimidine-Annulated Triazole Derivatives and Their Use in Platelet Aggregation Inhibition | BEIJING HONGHUI MEDITECH CO., LTD (CN) | 2025-02-27 | — | — | US | disclosed |
| EP-4146659-B1 | RING-FUSED 2-PYRIDONE COMPOUNDS, METHODS FOR PREPARATION THEREOF AND THEIR USE IN THE TREATMENT AND/OR PREVENTION OF A DISEASE INVOLVING GRAM-POSITIVE BACTERIA | QURETECH BIO AB (SE) | 2025-02-26 | — | — | EP | disclosed |
| US-12221459-B2 | Cancer treatment with (2,2-bishydroxymethyl) methylenecyclopropane nucleotides | MEDIVIR AB (SE) | 2025-02-11 | — | — | US | disclosed |
| WO-2025003469-A1 | PREVENTION, INHIBITION OR TREATMENT OF CONDITIONS OR DISORDERS MEDIATED BY UROCANATE REDUCTASE | IMPLEXION PHARMA AB (SE) | 2025-01-02 | — | — | WO | disclosed |
| EP-4448525-A1 | PYRIMIDINE-ANNULATED TRIAZOLE DERIVATIVES AND THEIR USE IN PLATELET AGGREGATION INHIBITION | Beijing Honghui Meditech Co., Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| WO-1997026065-A1 | PROCESSES FOR DEIONIZATION AND DEMINERALIZATION OF FLUIDS | CULLIGAN INTERNATIONAL COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0191813-B1 | SYNTHETIC POLYPEPTIDES AND ANTIBODIES RELATED TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN | SCRIPPS CLINIC RES (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5122448-A | Mixing sample with polypeptide, determining presence of immunoreaction | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-06-16 | — | — | US | disclosed |
| US-5116725-A | Colorimetric, diagnosis | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-05-26 | — | — | US | disclosed |
| US-RE33897-E | For diagnosis and treatment, vaccines | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0428629-A4 | SYNTHETIC POLYPEPTIDES AND ANTIBODIES RELATED TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN | — | 1991-12-27 | — | — | EP | disclosed |
| EP-0428629-A1 | SYNTHETIC POLYPEPTIDES AND ANTIBODIES RELATED TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN. | SCRIPPS CLINIC RES (US) | 1991-05-29 | — | — | EP | disclosed |
| WO-1990001495-A1 | SYNTHETIC POLYPEPTIDES AND ANTIBODIES RELATED TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-02-22 | — | — | WO | disclosed |
| US-4654419-A | Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1987-03-31 | — | — | US | disclosed |
| WO-1986001210-A1 | SYNTHETIC POLYPEPTIDES AND ANTIBODIES RELATED TO EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1986-02-27 | — | — | WO | disclosed |